Table 1.
Selected data from three multicentre trials of HES
First author | Population studied | No enrolled | Test group | Control | No (%) with outcome (intervention v control) | |||
---|---|---|---|---|---|---|---|---|
28 day mortality | 90 day mortality | Requiring renal replacement therapy | Use of blood products | |||||
Brunkhorst1 | Severe sepsis | 600 | 10% HES 200/0.5 | Ringer’s lactate | 70/262 (26.7) v 66/274 (24.1), P=0.48 | 107/261 (41.0) v 93/274 (33.9), P=0.09 | 81/261 (31.0) v 51/272 (18.8), P=0.001* | Exposure to red cell transfusions (over 21 days): 189/275 (68.7) v199/262 (76), P=0.06 |
Myburgh2 | Intensive care | 7000 | 6% HES 130/0.4 | 0.9% NaCl | 458/3313 (13.8) v 437/3331 (13.1), P=0.40 | 597/3315 (18.0) v 566/3336 (17.0), P=0.26 | 235/3352 (7.0) v 196/3375 (5.8), P=0.04† | Mean (SD) daily volume of blood products (first four days): 78 (250) ml v 60 (190) mL, P<0.001 |
Perner3 | Severe sepsis | 804 | 6% HES 130/0.4 | Ringer’s acetate | 154/398 (38.7) v 144/400 (36.0), P=0.43 | 201/398 (50.5) v 172/400 (43.0); P=0.03 | 87/398 (21.9) v 65/400 (16.3), P=0.04† | Exposure to blood product transfusion: 243/376 (64.6) v 204/380 (53.7), P=0.003 |
Severe bleeding (clinical bleeding requiring ≥3 units of packed red cells within 24 hours) 38/398 (9.5) v 25/400 (6.3), P=0.09 |
*At 21 days.
†At 90 days.